文献速递糖尿病

常规诊疗中接受SGLT2抑制剂或GLP-1受体激动剂的2型糖尿病患者匹配队列肾脏结局比较

Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
PubMed 文献 · Diabetologia · 2024-08-23

这项多中心回顾性观察研究比较了2型糖尿病患者使用SGLT2抑制剂与GLP-1受体激动剂的肾脏结局。倾向评分匹配后每组5701人,中位随访2.1年,SGLT2i组eGFR较GLP-1RA组高1.2 ml/min per 1.73 m2,白蛋白尿变化无差异,SGLT2i组CKD分级恶化率更低且血压改善更有利,尽管HbA1c降幅较小。

要点

  • 匹配后每组5701人,SGLT2i组eGFR全程较GLP-1RA组高1.2 ml/min per 1.73 m2。
  • 两组白蛋白尿变化无差异,SGLT2i组CKD分级恶化率更低且血压改善更有利。
  • 基线无CKD者中SGLT2i减少eGFR下降优于GLP-1RA。

核心结论

  • 在2型糖尿病患者中,SGLT2i治疗与GLP-1RA相比与更好的肾功能保护相关,表现为eGFR下降更慢。
  • 这些发现强化了SGLT2i作为该患者人群肾脏保护首选药物的地位。

研究设计与样本

  • 多中心回顾性观察研究,纳入糖尿病药物新使用者,采用倾向评分匹配。
  • 匹配后每组5701人,主要终点为eGFR变化,采用混合效应模型分析。
  • 次要终点包括基于eGFR的分类结局和白蛋白尿变化,并进行了亚组和敏感性分析。

主要发现

  • 中位随访2.1年,从基线87 ml/min per 1.73 m2起,SGLT2i组eGFR在整个观察期较GLP-1RA组高1.2 ml/min per 1.73 m2。
  • 白蛋白尿变化两组间未检测到差异。
  • SGLT2i组CKD分级恶化率更低,血压变化更有利,尽管HbA1c降幅较小。
  • 在基线无CKD的参与者中,SGLT2i减少eGFR下降优于GLP-1RA。

临床怎么用

  • 原文结论认为这些发现强化了SGLT2i作为该患者人群肾脏保护首选药物的地位。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We compared the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal outcomes in individuals with type 2 diabetes, focusing on the changes in eGFR and albuminuria. METHODS: This was a multicentre retrospective observational study on new users of diabetes medications. Participant characteristics were assessed before and after propensity score matching. The primary endpoint, change in eGFR, was analysed using mixed-effects models. Secondary endpoints included categorical eGFR-based outcomes and changes in albuminuria. Subgroup and sensitivity analyses were performed to assess robustness of the findings. RESULTS: After matching, 5701 participants/group were included. Participants were predominantly male, aged 61 years, with a 10 year duration of diabetes, a baseline HbA1c of 64 mmol/mol (8.0%) and BMI of 33 kg/m2. Chronic kidney disease (CKD) was present in 23% of participants. During a median of 2.1 years, from a baseline of 87 ml/min per 1.73 m2, eGFR remained higher in the SGLT2i group compared with the GLP-1RA group throughout the observation period by 1.2 ml/min per 1.73 m2. No differences were detected in albuminuria change. The SGLT2i group exhibited lower rates of worsening CKD class and favourable changes in BP compared with the GLP-1RA group, despite lesser HbA1c decline. SGLT2i also reduced eGFR decline better than GLP-1RA in participants without baseline CKD. CONCLUSIONS/INTERPRETATION: In individuals with type 2 diabetes, treatment with SGLT2i was associated with better preservation of renal function compared with GLP-1RA, as evidenced by slower decline in eGFR. These findings reinforce SGLT2i as preferred agents for renal protection in this patient population.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Fadini GP, Longato E, Morieri ML, et al. Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia. 2024. PMID: 39177691. doi:10.1007/s00125-024-06251-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。